<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>A Systemic Pathological Network Model and Combinatorial Intervention Strategies for Alzheimer's Disease - Health AI Hub</title>
    <meta name="description" content="This review conceptualizes Alzheimer's disease (AD) as a systemic pathological network involving AŒ≤, tau, and neuroinflammation, moving beyond the linear amyloi">
    <link rel="icon" type="image/svg+xml" href="../favicon.svg">
    <link rel="icon" type="image/png" sizes="32x32" href="../favicon-32x32.png">
    <link rel="icon" type="image/png" sizes="16x16" href="../favicon-16x16.png">
    <link rel="stylesheet" href="../styles.css">
</head>
<body>
    <header>
        <div class="container">
            <div class="breadcrumb">
                <a href="../index.html">‚Üê Back to all papers</a>
                <a href="../index.html" class="home-btn">üè† Home</a>
            </div>
        </div>
    </header>

    <main class="container paper-detail">
        <article>
            <h1>A Systemic Pathological Network Model and Combinatorial Intervention Strategies for Alzheimer's Disease</h1>

            <div class="paper-metadata">
                <div class="meta-row">
                    <strong>arXiv ID:</strong> <a href="http://arxiv.org/abs/2512.04937v1" target="_blank">2512.04937v1</a>
                </div>
                <div class="meta-row">
                    <strong>Published:</strong> 2025-12-04
                </div>
                <div class="meta-row">
                    <strong>Authors:</strong> She Xutong
                </div>
                <div class="meta-row">
                    <strong>Categories:</strong> q-bio.MN
                </div>
                <div class="meta-row">
                    <strong>Relevance Score:</strong> 1.00 / 1.00
                </div>
            </div>

            <div class="action-buttons">
                <a href="http://arxiv.org/abs/2512.04937v1" target="_blank" class="btn btn-primary">View on arXiv</a>
                <a href="https://arxiv.org/pdf/2512.04937v1" target="_blank" class="btn btn-primary">Download PDF</a>
            </div>

            <section class="paper-section">
                <h2>Summary</h2>
                <p class="summary-text">This review conceptualizes Alzheimer's disease (AD) as a systemic pathological network involving AŒ≤, tau, and neuroinflammation, moving beyond the linear amyloid cascade hypothesis. It advocates for early biomarker-based detection and comprehensive combination therapies, integrating emerging technologies like gene editing and AI, to fundamentally alter AD's trajectory towards preemptive, personalized management.</p>
            </section>

            <section class="paper-section">
                <h2>Medical Relevance</h2>
                <p>This paper offers a critical re-evaluation of Alzheimer's disease pathogenesis and therapy, providing a roadmap for developing more effective, personalized diagnostic and treatment strategies, which is crucial for managing this devastating neurological condition and improving patient outcomes.</p>
            </section>

            
            <section class="paper-section">
                <h2>AI Health Application</h2>
                <p>The paper envisions the use of AI for patient stratification, which is critical for guiding personalized and optimized combination interventions in Alzheimer's disease management. This implies AI will be used to analyze patient data (e.g., biomarker profiles) to categorize patients into specific groups, allowing for tailored treatment strategies.</p>
            </section>
            

            <section class="paper-section">
                <h2>Key Points</h2>
                <ul class="key-points">
                    
                    <li>AD pathogenesis is re-conceptualized as a complex, interacting network of AŒ≤, tau, and neuroinflammation, beyond a simple linear amyloid cascade.</li>
                    
                    <li>Diagnostic paradigms have evolved to leverage biomarker-based strategies, such as the AT(N) framework, for early disease detection in preclinical or prodromal stages.</li>
                    
                    <li>While anti-AŒ≤ monoclonal antibodies (e.g., lecanemab, donanemab) represent a breakthrough, their modest efficacy underscores the inherent limitations of single-target therapeutic approaches.</li>
                    
                    <li>A compelling rationale exists for combination therapies that simultaneously target AŒ≤ pathology, aberrant tau, and neuroinflammation to achieve superior clinical outcomes.</li>
                    
                    <li>Emerging technological platforms, including gene editing and biophysical neuromodulation, are emphasized as crucial for advancing precision medicine in AD.</li>
                    
                    <li>Future AD management will integrate early biomarker detection, multi-target therapeutic strategies, and AI-driven patient stratification.</li>
                    
                    <li>The ultimate goal is the implementation of preemptive, biomarker-guided, and personalized combination interventions to fundamentally change the disease course of AD.</li>
                    
                </ul>
            </section>

            <div class="two-column">
                <section class="paper-section">
                    <h2>Methodology</h2>
                    <p>This paper is a comprehensive review and synthesis of current scientific understanding regarding Alzheimer's disease pathogenesis, diagnostic paradigms, and therapeutic strategies. It critically analyzes existing literature to propose a systemic pathological network model and future directions for intervention.</p>
                </section>

                <section class="paper-section">
                    <h2>Key Findings</h2>
                    <p>The key findings highlight that AD is a multi-pathological network disease; biomarker-based diagnostics are critical for early intervention; current single-target therapies have limited efficacy; combination therapies targeting AŒ≤, tau, and neuroinflammation are essential; and advanced technologies (gene editing, neuromodulation, AI) are crucial for future precision medicine in AD.</p>
                </section>
            </div>

            <section class="paper-section">
                <h2>Clinical Impact</h2>
                <p>This work will likely inform a paradigm shift towards early, biomarker-guided AD diagnosis and the development of novel multi-target combination therapies. It promotes personalized medicine approaches tailored to individual patient profiles and encourages the integration of advanced technologies into future clinical practice for more effective AD management.</p>
            </section>

            
            <section class="paper-section">
                <h2>Limitations</h2>
                <p>The abstract implicitly notes the significant limitation of current single-target anti-AŒ≤ therapies, citing their "modest efficacy." It also suggests the inherent complexity and challenges in developing and implementing effective multi-target combination therapies for a disease with such an intricate pathological network.</p>
            </section>
            

            
            <section class="paper-section">
                <h2>Future Directions</h2>
                <p>Suggested future directions include further research and development into multi-target combination therapeutic strategies, exploration and integration of emerging technologies like gene editing and biophysical neuromodulation, development of AI-driven patient stratification methods, and a strong focus on establishing preemptive, biomarker-guided, and personalized combination interventions.</p>
            </section>
            

            <section class="paper-section">
                <h2>Medical Domains</h2>
                <div class="tags">
                    
                    <span class="tag">Neurology</span>
                    
                    <span class="tag">Neurodegeneration</span>
                    
                    <span class="tag">Geriatrics</span>
                    
                    <span class="tag">Pharmacology</span>
                    
                    <span class="tag">Diagnostics</span>
                    
                    <span class="tag">Precision Medicine</span>
                    
                </div>
            </section>

            <section class="paper-section">
                <h2>Keywords</h2>
                <div class="tags">
                    
                    <span class="tag tag-keyword">Alzheimer's disease</span>
                    
                    <span class="tag tag-keyword">amyloid-Œ≤</span>
                    
                    <span class="tag tag-keyword">tau pathology</span>
                    
                    <span class="tag tag-keyword">neuroinflammation</span>
                    
                    <span class="tag tag-keyword">combination therapy</span>
                    
                    <span class="tag tag-keyword">multi-target therapy</span>
                    
                    <span class="tag tag-keyword">precision medicine</span>
                    
                    <span class="tag tag-keyword">biomarkers</span>
                    
                </div>
            </section>

            <section class="paper-section">
                <h2>Abstract</h2>
                <p class="abstract">Alzheimer's disease (AD) persists as a paramount challenge in neurological research, characterized by the pathological hallmarks of amyloid-$Œ≤$ (A$Œ≤$) plaques and neurofibrillary tangles composed of hyperphosphorylated tau. This review synthesizes the evolving understanding of AD pathogenesis, moving beyond the linear amyloid cascade hypothesis to conceptualize the disease as a cross-talk of intricately interacting pathologies, encompassing A$Œ≤$, tau, and neuroinflammation as the foundation of phase-adapted pathological network model. This evolving pathophysiological understanding parallels a transformation in diagnostic paradigms, where biomarker-based strategies such as the AT(N) framework enable early disease detection during preclinical or prodromal stages. Within this new landscape, while anti-A$Œ≤$ monoclonal antibodies (e.g., lecanemab, donanemab), represent a breakthrough as the first disease-modifying therapies, their modest efficacy underscores the limitation of single-target approaches. Therefore, I explore the compelling rationale for combination therapies that simultaneously target A$Œ≤$ pathology, aberrant tau, and neuroinflammation. Looking forward, I emphasize emerging technological platforms such as gene editing and biophysical neuromodulation in advancing precision medicine. Ultimately, the integration of early biomarker detection, multi-target therapeutic strategies, and AI-driven patient stratification charts a promising roadmap toward fundamentally altering the trajectory of AD. The future of AD management will be defined by preemptive, biomarker-guided, and personalized combination interventions.
Keywords: Alzheimer's disease, amyloid-$Œ≤$, tau pathology, neuroinflammation, combination therapy, multi-target therapy, precision medicine, biomarkers</p>
            </section>

            
            <section class="paper-section">
                <h2>Comments</h2>
                <p>23 pages</p>
            </section>
            

            
        </article>
    </main>

    <footer class="container">
        <p><a href="../index.html">‚Üê Back to all papers</a></p>
    </footer>
</body>
</html>